[1]
Herbert, A.A., Glaab, D. and Schreiber, R. 2020. A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 4, 5 (Sep. 2020), s35. DOI:https://doi.org/10.25251/skin.4.supp.35.